Toward Value-Based Pricing to Boost Cancer Research and Innovation
- 31 May 2016
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (11) , 3127-3129
Abstract
The high market price of new anticancer agents has stimulated debate about the long-term sustainability of healthcare systems and whether these new agents can continue to be supported by public healthcare or by private insurers. In addition, some drugs have been approved with limited clinical benefit, raising concerns about setting a minimum requirement for medical benefit. Options to resolve these problems include raising the bar for approval of new drugs and/or pricing of new agents based on the medical benefit that they offer to patients. In this commentary, we suggest that new agents should be marketed in a two-step process that would include first the approval of the new drug by the regulatory agencies and second the introduction of a market price based on the medical benefit that the new intervention offers to patients. Introduction of value-based pricing would maintain the sustainability of health care systems and would improve drug development, as it would pressure pharmaceutical companies to become more innovative and avoid the development of compounds with limited benefit. Value-based pricing could also stimulate the funding of research directed to development of new anticancer drugs with novel mechanisms of action. Cancer Res; 76(11); 1–3. ©2016 AACR.Keywords
This publication has 15 references indexed in Scilit:
- Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions?Mayo Clinic Proceedings, 2015
- Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trialsAnnals of Oncology, 2013
- Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic DrugsJournal of Clinical Oncology, 2011
- Demythologizing the high costs of pharmaceutical researchBioSocieties, 2011
- When Are "Positive" Clinical Trials in Oncology Truly Positive?JNCI: Journal of the National Cancer Institute, 2010
- Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug ApprovalJournal of Clinical Oncology, 2009
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Drug development cost estimates hard to swallowCanadian Medical Association Journal, 2009
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Guidelines for Pharmacoeconomic StudiesPharmacoEconomics, 1997